[The distribution and polymorphism of beta-2-adrenoreceptors in the bronchi].
Genic variability has a role in bronchial asthma susceptibility and the influence of its gravity, and also influences therapy efficacy. Clinical trials demonstrated that beta2 adrenoreceptors variability has an influence on the response to bronchodilator therapy. Some mutations induce resistance to bronchial asthma occurrence (Q27E which reduces down-regulation), others make subjects susceptible to asthma (D79N, T1641 and most of all R16G by an intensive down-regulation), and a third kind of mutations has no influence whatsoever on this disease (1159L, 1159F, K375R). A better understanding of the molecular processes involved in different pathways in asthma can lead to pathophysiological details, to find a more efficient treatment.